Drugs / ORIC-114
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06816992 | Feb 2025 → Dec 2026 expected | non-small cell lung carcinoma | ORIC Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT06012721 | Sep → Nov 2023 | — | ORIC Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05315700 | Mar 2022 → Sep 2026 overdue | cancer | ORIC Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORIC-114 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06012721 ↗ |
| Action | Inhibit | “irreversible small molecule inhibitor designed to target EGFR and HER2 alterations” NCT05315700 ↗ |
| Modality | Small molecule | “ORIC-114 is a brain penetrant, selective, orally bioavailable, irreversible small molecule inhibitor designed to target EGFR and HER2 alterations” NCT05315700 ↗ |
| Route | Oral | “ORIC-114 oral daily” NCT05315700 ↗ |
| Target | EGFR | “ORIC-114 is a brain penetrant, selective, orally bioavailable, irreversible small molecule inhibitor designed to target EGFR and HER2 alterations” NCT05315700 ↗ |
| Target | HER2 | “ORIC-114 is a brain penetrant, selective, orally bioavailable, irreversible small molecule inhibitor designed to target EGFR and HER2 alterations” NCT05315700 ↗ |